Skip to main content
. 2018 Feb 1;217(10):1616–1625. doi: 10.1093/infdis/jiy065

Figure 2.

Figure 2.

Study flow. The 30RSV-PreF group received nonadjuvanted RSV vaccine containing 30 µg of RSV–prefusion F protein (PreF), the 60RSV-PreF group received nonadjuvanted RSV vaccine containing 60 µg of RSV PreF, the 60RSV-PreF-Al group received aluminum-adjuvanted RSV vaccine containing 60 µg of RSV PreF, and the Tdap group received an adult formulation of combined tetanus toxoid-diphtheria toxoid-acellular pertussis vaccine. ATP, according to protocol.